RegeneRex Pharma appoints Troy Thuet as COO; Dr. Lee Ori becomes Chief R&D Officer

REGENEREX PHARMA, INC.

Troy Thuet appointed COO effective Jan 14, 2022; over 15 years of managerial and executive experience.
Dr. Lee Ori transitions from COO to Chief R&D Officer; holds PharmD from Auburn, formerly at Eli Lilly.
No departure or compensation details disclosed in the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Lee Ori

Chief R & D Officer

RGPX · REGENEREX PHARMA, INC.

Effective: 2022-01-14
Successor: Troy Thuet
Filed: January 18, 2022, 6:59 PM ET

He is replacing Dr. Lee Ori who has been appointed as Chief R & D Officer of the Company for the coming year.

Appointed

Troy Thuet

Chief Operating Officer

RGPX · REGENEREX PHARMA, INC.

Effective: 2022-01-14
Filed: January 18, 2022, 6:59 PM ET

Effective January 14, 2022, Mr. Troy Thuet has been appointed to serve as Chief Operating Officer of the Company for the coming year.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Lee Ori was appointed as Chief R & D Officer at REGENEREX PHARMA, INC..

Action: appointed
Role: Chief R & D Officer

Exact text from the filing

He is replacing Dr. Lee Ori who has been appointed as Chief R & D Officer of the Company for the coming year.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Troy Thuet was appointed as Chief Operating Officer at REGENEREX PHARMA, INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Effective January 14, 2022, Mr. Troy Thuet has been appointed to serve as Chief Operating Officer of the Company for the coming year.

View on SEC.gov

REGENEREX PHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001472375-22-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.